Identification and characterization of the intercellular adhesion molecule-2 gene as a novel p53 target

Supplementary Materials
Supplementary Figure S1: Endogenous p53 upregulates ICAM2 protein and mRNA levels. (A) HCT116-p53(+/+) and HCT116-p53(−/−) cells were treated with 0.5 μg/mL ADR, 20 μg/mL 5-FU, or 10 μM Nutlin-3 for 24 h. Immunoblot analyses of ICAM2, p53, p21, PIG3, β-actin, p73, and p63 were conducted. The primary antibodies used for p73/p63 immunoblot are as follows: mouse anti-human p73 monoclonal antibody (mAb) (5B429, (Santa Cruz Biotechnology), ER-15 (Oncogene Research), and GC-15 (Oncogene Research)); mouse anti-human p63 mAb (4A4 (Santa Cruz Biotechnology) and Y4A3 (Thermo Scientific)); rabbit anti-human p63 polyclonal Ab (N2C1, Genetex Inc.). (B) Cells were treated as described above, and ICAM2 mRNA levels were assayed by real-time RT-PCR. Relative gene expression levels were quantified using the ΔΔCt method and the results were normalized to the expression of the GAPDH gene. The data are shown as the mean ± standard errors of 3 independent experiments and were normalized to their respective controls as 1. promoter. Oligonucleotide primer sequences are as follows: ICAM2 RE1 sense 5′-GCGACACTTCAACCTTCTTGCC-3′, ICAM2 RE1 antisense 5′-CCCTGCCTCCCTGAGCTCCT-3′; ICAM2 RE2/3 sense 5′-TGCGTGTATGAGACGTGTGCA-3′, ICAM2 RE2/3 antisense 5′-AGCCTGGGCGACAAGAGTGAG-3′; ICAM2 RE4 sense 5′-GGTGCCCACCACCTTGCATAC-3′, ICAM2 RE4 antisense 5′-GGGTCCTTCAGACCAGCCTGC-3′; and MDM2 promoter sense 5′-GTTCAGTGGGCAGGTTGACT-3′, MDM2 promoter antisense 5′-GCTACAAGCAAGTCGGTGCT-3′. To ensure that PCR amplification was performed in the linear range, template DNA was amplified for a maximum of 40 cycles.
Supplementary Figure S3:
The effect of mutant-p53 and ΔNp53 on ICAM2 expression. (A) Cells were transfected with various mutant p53-expressing plasmids or a wild-type p53-expressing plasmid. Cells were harvested 48 h after transfection, and immunoblot analysis was performed using an anti-ICAM2 Ab. p53 mutant constructs encoding p53 mutants commonly seen in human cancers (R175H R248Q, R249S, R273C, and R282W) were generated by subcloning into the pcDNA3.2 plasmid with an N-terminal FLAG epitope tag (Invitrogen). (B) HCT116-p53(−/−) cells were transfected with empty or FLAG-tagged mutant-p53-expressing vectors. After 8 h, cells were then transfected with wt-p53-expressing plasmid (no FLAG) for 24 h. ICAM2 induction by ectopic expression of wild-type p53 was partially reversed by all p53 mutants, indicating that certain p53 mutants indeed have a dominant negative effect against exogenous p53 on the regulation of ICAM2. (C) HCT116-p53(+/+) and HCT116-p53(−/−) cells were transfected with empty, wild-type p53-, or ΔNp53 (Δ40p53α)-expressing vectors and were harvested 24 h after transfection.ICAM2 and p53 protein levels were determined by immunoblot analysis . p53 immunoblot was performed using the rabbit anti-human p53 polyclonal Ab (FL393, Santa Cruz Biotechnology), which recognizes amino acids 1-393 of human p53. A ΔNp53 construct was generated by subcloning into the pF5K-CMV-neo plasmid (Promega). Additionally, we performed a multigene sequencing screen interrogating 2855 mutational hotspots in 50 cancerrelated genes using the AmpliSeq Cancer Hotspot Panel v2 and Ion Torrent semiconductor sequencer. This panel can explore hotspot regions of the following 50 cancer-associated genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, JAK2, JAK3, IDH1, IDH2, KDR/ VEGFR2, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL. Library preparation and sequencing with an Ion Torrent PGM was performed as previously described (J Mol Diagn. 2013; 5:607-22) . Approximately 800X average coverage was obtained with > 98% of target bases having at least 100 sequence reads. Alignment to the hg19 genome and variant calling was performed by Ion Reporter Software 4.0.
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